These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16832915)

  • 21. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem-cell-derived products: an FDA update.
    Moos M
    Trends Pharmacol Sci; 2008 Dec; 29(12):591-3. PubMed ID: 18937983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac repolarization and the safety of new drugs defined by electrocardiography.
    Morganroth J
    Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan.
    Koga J
    Dev Biol Stand; 1996; 88():152-3. PubMed ID: 9119130
    [No Abstract]   [Full Text] [Related]  

  • 26. Britain adopts more stringent rules for phase I trials of high-risk compounds.
    Sinha G
    J Natl Cancer Inst; 2007 Jun; 99(12):915-7. PubMed ID: 17565146
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.
    Liedert B; Bassus S; Schneider CK; Kalinke U; Löwer J
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):1-9. PubMed ID: 17256444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem cells ready for prime time.
    Wadman M
    Nature; 2009 Jan; 457(7229):516. PubMed ID: 19177087
    [No Abstract]   [Full Text] [Related]  

  • 29. Geron gets green light for human trial of ES cell-derived product.
    Alper J
    Nat Biotechnol; 2009 Mar; 27(3):213-4. PubMed ID: 19270655
    [No Abstract]   [Full Text] [Related]  

  • 30. Microdosing in early lead discovery.
    Jekunen AP; Pauwels EK; Kairemo KJ
    Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent developments in the protection of pediatric research subjects.
    Flotte TR; Frentzen B; Humphries MR; Rosenbloom AL
    J Pediatr; 2006 Sep; 149(3):285-286. PubMed ID: 16939731
    [No Abstract]   [Full Text] [Related]  

  • 32. Bad to the bone.
    Kimes M
    Fortune; 2012 Oct; 166(6):140-52, 154. PubMed ID: 23072076
    [No Abstract]   [Full Text] [Related]  

  • 33. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 34. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human microdosing; a boon or a bane?
    Seth SD; Kumar NK; Dua P
    Indian J Med Res; 2009 Aug; 130(2):202-4. PubMed ID: 19797820
    [No Abstract]   [Full Text] [Related]  

  • 36. Opinion: Microdosing: safer clinical trials and fewer animal tests.
    Langley G; Farnaud S
    Bioanalysis; 2010 Mar; 2(3):393-5. PubMed ID: 21083249
    [No Abstract]   [Full Text] [Related]  

  • 37. Artificial lenses for the eye.
    Greene JF
    FDA Consum; 1978 Feb; 12(1):21-3. PubMed ID: 10316574
    [No Abstract]   [Full Text] [Related]  

  • 38. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for reform of the IND/NDA processes: part II.
    Romansky MA
    J Clin Psychopharmacol; 1982 Dec; 2(6):424-6. PubMed ID: 7174868
    [No Abstract]   [Full Text] [Related]  

  • 40. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
    van Gerven J; Bonelli M
    Br J Clin Pharmacol; 2018 Jul; 84(7):1401-1409. PubMed ID: 29451320
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.